Survodutide Latest Research: New Indications, Trials & What’s Coming

Introduction

Survodutide is among the most-watched investigational drugs for combined obesity and liver disease. Boehringer Ingelheim and Zealand Pharma’s joint Phase 3 program covers two main indications: obesity (SYNCHRONIZE trials) and MASH liver disease (LIVERAGE program). Expected readouts span 2026 and 2027 with potential FDA submission in 2027 and approval in 2028.

The MASH Phase 2 results published by Sanyal and colleagues in 2024 in the New England Journal of Medicine were striking. Survodutide produced NASH resolution in 83 percent of high-dose participants compared to 18 percent on placebo, with fibrosis improvement in 35 to 40 percent. These numbers exceed both resmetirom (the first FDA-approved MASH drug) and other GLP-1-class drugs tested for MASH.

The obesity Phase 2 results published by le Roux and colleagues in 2024 in The Lancet showed 14.9 percent weight loss at 46 weeks, comparable to semaglutide’s STEP 1 results. The combination of MASH efficacy and meaningful weight loss positions survodutide for a unique market position.

This article covers the active SYNCHRONIZE and LIVERAGE programs, completed Phase 2 studies, exploratory work in additional indications, and the expected pipeline progression. TrimRx provides personalized treatment plans for currently approved GLP-1 medications while survodutide moves through regulatory review.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the SYNCHRONIZE Program?

SYNCHRONIZE is Boehringer Ingelheim’s umbrella name for the obesity Phase 3 program. Two trials are running.

Quick Answer: SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (T2D and obesity), and LIVERAGE-1 and LIVERAGE-2 (MASH) are the major Phase 3 programs

SYNCHRONIZE-1 enrolled approximately 700 adults with obesity (BMI 30 or higher, or BMI 27 with comorbidity) without diabetes. Primary endpoint is percent change in body weight at 76 weeks. This is the registration trial for the obesity indication.

SYNCHRONIZE-2 enrolled adults with type 2 diabetes and overweight or obesity. Primary endpoints include weight loss and A1C change at 76 weeks.

Topline data from both trials is expected in 2026. FDA submission for the obesity indication could come in late 2026 or early 2027.

What Is the LIVERAGE Program?

LIVERAGE is the Phase 3 MASH program. The trials enrolled adults with biopsy-confirmed MASH and significant fibrosis (F2 or F3 stage).

LIVERAGE-1 is the smaller trial reading out earlier with histologic outcomes at 52 weeks. LIVERAGE-2 is the larger long-term outcomes trial running 5 years to assess fibrosis progression and clinical liver outcomes.

Histologic endpoints include NASH resolution without worsening fibrosis, fibrosis improvement of at least 1 stage, and combined endpoint of both. These align with FDA-accepted surrogate endpoints for MASH approval.

LIVERAGE-1 readout is expected in 2026 with potential FDA submission for the MASH indication in 2026 or 2027.

What Did Phase 2 Obesity Data Show?

The Phase 2 obesity trial (le Roux et al. 2024 Lancet) enrolled 387 adults with obesity (mean BMI 37) without diabetes. Participants were randomized to placebo or survodutide at 0.6, 2.4, or 4.8 mg weekly for 46 weeks.

The 4.8 mg group lost a mean of 14.9 percent of baseline body weight. The 2.4 mg group lost 11.8 percent. Both numbers exceed placebo (2.8 percent) substantially.

Response rates at the high dose:

• 83 percent achieved 5 percent or greater loss
• 67 percent achieved 10 percent or greater loss
• 38 percent achieved 15 percent or greater loss

The shape of the weight loss curve mattered. The curve was still trending down at week 46, suggesting longer treatment might produce further loss. SYNCHRONIZE’s 76-week design will test this.

Body composition analysis showed fat mass accounted for the majority of weight lost, with lean mass loss representing about 22 percent of total weight loss, similar to dietary weight loss and to other GLP-1s.

What Did Phase 2 MASH Data Show?

Sanyal and colleagues published Phase 2 MASH results in 2024 in NEJM. The trial randomized 295 adults with biopsy-confirmed MASH and significant fibrosis to placebo or survodutide at 2.4, 4.8, or 6.0 mg weekly for 48 weeks.

Primary endpoint was histologic NASH resolution without worsening fibrosis. The 6.0 mg group achieved this in 83 percent of participants. The 4.8 mg group achieved 64 percent. Placebo: 18 percent.

Fibrosis improvement of at least 1 stage was achieved in 35 to 40 percent of high-dose participants, compared to 22 percent on placebo. This is meaningful improvement suggesting survodutide could reverse early to mid-stage liver scarring.

MRI-PDFF liver fat content reduced by 67 percent at the high dose, putting the majority of participants below the steatosis threshold by week 48.

These results compare favorably to resmetirom (Rezdiffra®) Phase 3 MAESTRO-NASH (NEJM 2024) which showed roughly 30 percent NASH resolution rates. Survodutide could become the first weight-loss-active MASH treatment.

How Does Survodutide Compare with Other MASH Drugs in Development?

Several drugs are in MASH development. Resmetirom is the first approved. Survodutide is the leading GLP-1-class candidate for MASH.

Tirzepatide is being tested for MASH in SYNERGY-NASH. Phase 2 results showed NASH resolution rates around 51 percent at the high dose, lower than survodutide’s 83 percent. The difference likely reflects the glucagon receptor activity in survodutide that drives stronger hepatic effects.

Semaglutide phase 2 NASH data (Newsome 2021 NEJM) showed 59 percent NASH resolution at the high dose, with limited fibrosis improvement. Semaglutide MASH Phase 3 ESSENCE program is in progress.

Pegozafermin (a long-acting FGF21 analog) and efinopegdutide (GLP-1/glucagon dual agonist similar to survodutide) are also in development. The competitive landscape is becoming crowded.

Are There Cardiovascular Outcomes Trials for Survodutide?

Yes. A dedicated cardiovascular outcomes trial is enrolling adults with established atherosclerotic cardiovascular disease and overweight or obesity. The design mirrors SELECT (Lincoff et al. 2023 NEJM) which showed 20 percent MACE reduction on semaglutide.

The survodutide CV trial is in earlier stages than SYNCHRONIZE or LIVERAGE. Topline data is expected in 2028 or 2029.

The cardiovascular benefit hypothesis is strong. Phase 2 data shows blood pressure reduction, weight loss, and improved cardiometabolic profile that should translate to cardiovascular outcomes.

Key Takeaway: Phase 2 MASH results (Sanyal et al. 2024 NEJM) showed 83 percent NASH resolution on the 6.0 mg dose, exceeding any other GLP-1 class drug tested for MASH

What About Heart Failure Indications?

The STEP-HFpEF program established semaglutide for heart failure with preserved ejection fraction in adults with obesity. Survodutide’s combined weight loss and metabolic effects raise interest in similar indications.

A Phase 2 trial of survodutide in HFpEF is in planning stages. The glucagon receptor activity is the wildcard. Glucagon increases resting energy expenditure, which is helpful for weight loss but could theoretically increase cardiac workload in fragile heart failure patients.

Phase 2 data will inform whether HFpEF is a fit or a contraindication.

What About Obstructive Sleep Apnea?

OSA is heavily driven by obesity. Tirzepatide became FDA-approved for OSA in December 2024 based on SURMOUNT-OSA. Survodutide could follow a similar path if Phase 3 obesity trial subset analyses show OSA benefit.

A dedicated OSA Phase 3 trial for survodutide has not been announced. The OSA market may go to tirzepatide and retatrutide before survodutide enters.

Are There Other Indications Being Explored?

Type 1 diabetes adjunctive therapy is being studied. The dual mechanism could provide weight loss and glycemic stabilization in T1D patients who often struggle with weight gain on insulin. Phase 2 work is in early stages.

Polycystic ovary syndrome is another consideration. The dual mechanism could address both metabolic and reproductive aspects of PCOS.

Alcohol use disorder research is underway following anecdotal reports of reduced alcohol consumption on GLP-1 drugs. Survodutide’s mechanism makes it a candidate for this research direction.

These exploratory indications are years away from approval if they progress.

What’s the Timeline for FDA Approval?

Boehringer Ingelheim has not announced specific submission dates. Reasonable expectations based on trial timelines:

• LIVERAGE-1 readout: 2026
• MASH FDA submission: late 2026 or early 2027
• MASH approval: 2027 or 2028
• SYNCHRONIZE readouts: 2026
• Obesity FDA submission: 2027
• Obesity approval: 2028
• Cardiovascular outcomes readout: 2028 or 2029
• Real-world availability for MASH and obesity: 2028 or later

These timelines could shift earlier or later based on trial results, FDA review timelines, and supply chain readiness.

What Does the Competitive Landscape Look Like?

For MASH, survodutide leads the GLP-1-class candidates. Tirzepatide SYNERGY-NASH and semaglutide ESSENCE programs are direct competitors. Resmetirom (Rezdiffra) is the only approved MASH drug.

For obesity, survodutide enters a crowded field. Semaglutide (Wegovy®), tirzepatide (Zepbound®), and retatrutide (expected 2026 to 2027 approval) will be available. Survodutide’s positioning will likely emphasize the MASH benefit.

For combined obesity and liver disease, survodutide may have unique positioning as the only weight-loss-active MASH drug.

Bottom line: The Phase 3 program is led by the MASH indication, with potential MASH approval before or alongside obesity approval

FAQ

When Will Survodutide Be Available to Patients?

Expected 2027 or 2028 depending on indication. MASH approval may come first.

What’s the Difference Between Survodutide and Retatrutide?

Survodutide is GLP-1 plus glucagon. Retatrutide is GLP-1 plus GIP plus glucagon. Retatrutide produces larger weight loss but survodutide has stronger hepatic effects in MASH.

Will Survodutide Be More Expensive Than Current GLP-1s?

Pricing is speculative. Expect launch pricing of $900 to $1,200 list price, similar to current GLP-1 drugs.

Is Survodutide Better for Diabetes or Obesity?

Phase 2 showed strong results in both populations. Type 2 diabetes patients may benefit from the dual mechanism.

Will Survodutide Be Approved for Both MASH and Obesity?

Yes, expected. MASH approval may precede obesity approval.

Can Survodutide Reverse Liver Disease?

Phase 2 showed 83 percent NASH resolution and improvement in fibrosis. Phase 3 LIVERAGE will confirm whether these effects sustain.

How Does Survodutide Affect Kidney Disease?

Not extensively studied. Phase 2 data suggests no specific renal concerns at mild to moderate CKD stages.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.